{"filings":[{"id":99156,"accession_number":"0001104659-26-055887","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).","Large pharma grew double-digits for sixth consecutive quarter; U.S. academic market stabilized with low-single-digit growth; emerging biotech spending still lagging.","Protein Sciences segment sales $226.2M (down 1% reported); segment margin 44.2% vs 45.6%.","Diagnostics & Spatial Biology segment sales $85.6M (down 4% reported, up 3% organic); segment margin improved to 12.1% from 9.4%.","Declared quarterly dividend $0.08 per share, payable May 29, 2026 to shareholders of record May 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":893847000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115005,"accession_number":"0001104659-26-013412","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.","Steve Crouse, previously SVP of Analytical Solutions, named successor; he joined in 2022 from Thermo Fisher Scientific.","Crouse's employment agreement includes base salary of $505,000, target cash bonus of 75% of base, and equity awards valued at ~$170,000 one-time and ~$1.2M annual target.","McManus's termination approved without cause; he will receive severance per employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115004,"accession_number":"0001104659-26-009994","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.","Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.","Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.","Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.","China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":582432000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131389,"accession_number":"0001104659-25-106631","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).","Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.","Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).","Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.","Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":286555000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147982,"accession_number":"0001558370-25-010393","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.","Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.","Protein Sciences segment organic growth 4% (reported 6%) in Q4.","Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.","Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1219635000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166702,"accession_number":"0001558370-25-006594","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 revenue $316.2M (+6% organic), adj EPS $0.56, declares $0.08 dividend and $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.","Protein Sciences segment organic growth 7% (reported 6%) on improved pharma demand and commercial execution.","Adjusted operating margin improved to 34.9% from 33.0% YoY; reported margin 12.2% (incl. charges).","Declared quarterly dividend $0.08/share, payable May 30, 2025 to holders of record May 19, 2025.","Board approved new $500M share repurchase program, effective May 8, 2025, replacing prior program."],"consensus_eps_estimate":0.4287,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":902671000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166701,"accession_number":"0001558370-25-006512","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Techne authorizes $500M share repurchase program, replacing prior 2022 authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $500M in common stock repurchases on April 30, 2025.","Replaces the prior $500M program approved February 2, 2022; no expiration date set.","Repurchases may be made in open market, private transactions, or block trades.","Management retains discretion based on market conditions, stock price, and capital needs.","Program intends to offset dilution from stock option exercises among other purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184122,"accession_number":"0001558370-25-002177","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Techne ordered to pay former CEO $35.98M over option expiration error","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.","Options expired August 9, 2024 per award agreements; company's platform erroneously showed October 26, 2024.","Interest of $980,000 and legal fees/costs of $234,000 also awarded to Kummeth.","Award calculated using average closing price of TECH common stock over 30 days before actual expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184121,"accession_number":"0001558370-25-000639","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.","Protein Sciences segment grew 8% organic; Diagnostics & Spatial Biology grew 12% organic.","Declared $0.08 per share quarterly dividend, payable Feb 28, 2025 to holders of record Feb 17, 2025.","Dr. Amy Herr appointed independent director effective Feb 1, 2025; serves on Science & Technology Committee."],"consensus_eps_estimate":0.5089,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":586489000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200713,"accession_number":"0001558370-24-014442","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Techne grants CFO James Hippel 34,634 RSUs to correct forfeited options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant date: October 30, 2024; vesting in three equal annual installments.","Award under 2020 Equity Incentive Plan; retention purpose cited.","Grant compensates for stock options forfeited due to administrative error in expiration date recording.","Shares: 34,634; subject to continued service and plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200712,"accession_number":"0001558370-24-013879","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.","Diagnostics & Spatial Biology segment organic growth 14%; cell and gene therapy workflow solutions strong.","Dividend of $0.08 per share declared, payable Nov 22 to holders of record Nov 11.","Annual meeting: board set at 9, all director nominees elected, say-on-pay approved, KPMG ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":289458000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216733,"accession_number":"0001558370-24-011193","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.","GAAP EPS $0.25 vs $0.47; adjusted EPS $0.49 vs $0.55.","Diagnostics & Genomics segment grew 9% organically in Q4.","FY2024 operating cash flow $299M, up 18% YoY.","Board declared $0.08 quarterly dividend payable Aug 30, record Aug 19."],"consensus_eps_estimate":null,"consensus_eps_actual":1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1159060000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236413,"accession_number":"0001558370-24-006319","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 FY2024: Revenue $303.4M (+2% organic); GAAP EPS $0.31 vs $0.43; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.","Diagnostics & Genomics segment organic growth 10% (reported 16%); record GMP reagent sales in cell/gene therapy.","Cash from operations $223.5M, up 31% YoY.","Quarterly dividend of $0.08 per share, payable May 24, 2024; record date May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":852961000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236412,"accession_number":"0001558370-24-006279","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).","She will serve on the Science & Technology Committee.","Dr. Klimovsky is EVP & Chief Development Officer at Genmab; previously held senior roles at Novartis Oncology and Bristol-Myers Squibb.","Board also approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254075,"accession_number":"0001558370-24-000683","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.","GAAP EPS $0.17 vs $0.31 YoY; adjusted EPS $0.40 vs $0.47.","Cash flow from operations $142.5M, up 18% YoY.","Board declared $0.08 per share quarterly dividend, payable Feb 26, 2024.","Dr. Matthew F. McManus appointed President of Diagnostics and Genomics segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":549533000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254074,"accession_number":"0001558370-24-000125","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.","McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.","McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.","Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.","McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}